Cargando…

Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics

BACKGROUND: The heat shock protein 90 (Hsp90) is required for the stability of many signalling kinases. As a target for cancer therapy it allows the simultaneous inhibition of several signalling pathways. However, its inhibition in healthy cells could also lead to severe side effects. This is the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Haupt, Armin, Joberty, Gerard, Bantscheff, Marcus, Fröhlich, Holger, Stehr, Henning, Schweiger, Michal R, Fischer, Axel, Kerick, Martin, Boerno, Stefan T, Dahl, Andreas, Lappe, Michael, Lehrach, Hans, Gonzalez, Cayetano, Drewes, Gerard, Lange, Bodo MH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342885/
https://www.ncbi.nlm.nih.gov/pubmed/22277058
http://dx.doi.org/10.1186/1471-2407-12-38
_version_ 1782231743081742336
author Haupt, Armin
Joberty, Gerard
Bantscheff, Marcus
Fröhlich, Holger
Stehr, Henning
Schweiger, Michal R
Fischer, Axel
Kerick, Martin
Boerno, Stefan T
Dahl, Andreas
Lappe, Michael
Lehrach, Hans
Gonzalez, Cayetano
Drewes, Gerard
Lange, Bodo MH
author_facet Haupt, Armin
Joberty, Gerard
Bantscheff, Marcus
Fröhlich, Holger
Stehr, Henning
Schweiger, Michal R
Fischer, Axel
Kerick, Martin
Boerno, Stefan T
Dahl, Andreas
Lappe, Michael
Lehrach, Hans
Gonzalez, Cayetano
Drewes, Gerard
Lange, Bodo MH
author_sort Haupt, Armin
collection PubMed
description BACKGROUND: The heat shock protein 90 (Hsp90) is required for the stability of many signalling kinases. As a target for cancer therapy it allows the simultaneous inhibition of several signalling pathways. However, its inhibition in healthy cells could also lead to severe side effects. This is the first comprehensive analysis of the response to Hsp90 inhibition at the kinome level. METHODS: We quantitatively profiled the effects of Hsp90 inhibition by geldanamycin on the kinome of one primary (Hs68) and three tumour cell lines (SW480, U2OS, A549) by affinity proteomics based on immobilized broad spectrum kinase inhibitors ("kinobeads"). To identify affected pathways we used the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway classification. We combined Hsp90 and proteasome inhibition to identify Hsp90 substrates in Hs68 and SW480 cells. The mutational status of kinases from the used cell lines was determined using next-generation sequencing. A mutation of Hsp90 candidate client RIPK2 was mapped onto its structure. RESULTS: We measured relative abundances of > 140 protein kinases from the four cell lines in response to geldanamycin treatment and identified many new potential Hsp90 substrates. These kinases represent diverse families and cellular functions, with a strong representation of pathways involved in tumour progression like the BMP, MAPK and TGF-beta signalling cascades. Co-treatment with the proteasome inhibitor MG132 enabled us to classify 64 kinases as true Hsp90 clients. Finally, mutations in 7 kinases correlate with an altered response to Hsp90 inhibition. Structural modelling of the candidate client RIPK2 suggests an impact of the mutation on a proposed Hsp90 binding domain. CONCLUSIONS: We propose a high confidence list of Hsp90 kinase clients, which provides new opportunities for targeted and combinatorial cancer treatment and diagnostic applications.
format Online
Article
Text
id pubmed-3342885
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33428852012-05-04 Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics Haupt, Armin Joberty, Gerard Bantscheff, Marcus Fröhlich, Holger Stehr, Henning Schweiger, Michal R Fischer, Axel Kerick, Martin Boerno, Stefan T Dahl, Andreas Lappe, Michael Lehrach, Hans Gonzalez, Cayetano Drewes, Gerard Lange, Bodo MH BMC Cancer Research Article BACKGROUND: The heat shock protein 90 (Hsp90) is required for the stability of many signalling kinases. As a target for cancer therapy it allows the simultaneous inhibition of several signalling pathways. However, its inhibition in healthy cells could also lead to severe side effects. This is the first comprehensive analysis of the response to Hsp90 inhibition at the kinome level. METHODS: We quantitatively profiled the effects of Hsp90 inhibition by geldanamycin on the kinome of one primary (Hs68) and three tumour cell lines (SW480, U2OS, A549) by affinity proteomics based on immobilized broad spectrum kinase inhibitors ("kinobeads"). To identify affected pathways we used the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway classification. We combined Hsp90 and proteasome inhibition to identify Hsp90 substrates in Hs68 and SW480 cells. The mutational status of kinases from the used cell lines was determined using next-generation sequencing. A mutation of Hsp90 candidate client RIPK2 was mapped onto its structure. RESULTS: We measured relative abundances of > 140 protein kinases from the four cell lines in response to geldanamycin treatment and identified many new potential Hsp90 substrates. These kinases represent diverse families and cellular functions, with a strong representation of pathways involved in tumour progression like the BMP, MAPK and TGF-beta signalling cascades. Co-treatment with the proteasome inhibitor MG132 enabled us to classify 64 kinases as true Hsp90 clients. Finally, mutations in 7 kinases correlate with an altered response to Hsp90 inhibition. Structural modelling of the candidate client RIPK2 suggests an impact of the mutation on a proposed Hsp90 binding domain. CONCLUSIONS: We propose a high confidence list of Hsp90 kinase clients, which provides new opportunities for targeted and combinatorial cancer treatment and diagnostic applications. BioMed Central 2012-01-25 /pmc/articles/PMC3342885/ /pubmed/22277058 http://dx.doi.org/10.1186/1471-2407-12-38 Text en Copyright ©2012 Haupt et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Haupt, Armin
Joberty, Gerard
Bantscheff, Marcus
Fröhlich, Holger
Stehr, Henning
Schweiger, Michal R
Fischer, Axel
Kerick, Martin
Boerno, Stefan T
Dahl, Andreas
Lappe, Michael
Lehrach, Hans
Gonzalez, Cayetano
Drewes, Gerard
Lange, Bodo MH
Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
title Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
title_full Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
title_fullStr Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
title_full_unstemmed Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
title_short Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
title_sort hsp90 inhibition differentially destabilises map kinase and tgf-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342885/
https://www.ncbi.nlm.nih.gov/pubmed/22277058
http://dx.doi.org/10.1186/1471-2407-12-38
work_keys_str_mv AT hauptarmin hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT jobertygerard hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT bantscheffmarcus hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT frohlichholger hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT stehrhenning hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT schweigermichalr hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT fischeraxel hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT kerickmartin hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT boernostefant hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT dahlandreas hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT lappemichael hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT lehrachhans hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT gonzalezcayetano hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT drewesgerard hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics
AT langebodomh hsp90inhibitiondifferentiallydestabilisesmapkinaseandtgfbetasignallingcomponentsincancercellsrevealedbykinasetargetedchemoproteomics